📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-07 10:34
712 analysed today
712
Today
133,601
All-time analysed
40,124
Positive
6,284
Negative
79,373
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
19 announcements match the current filters (relevance ≥ 5).
₹1,000 Cr Vizag Expansion and 25% QoQ Revenue Growth for Blue Jet Healthcare
Blue Jet Healthcare reported a strong start to FY27 with Q1 revenue of ₹293 Cr, a 25% sequential increase driven by the recovery of the Pharma Intermediates (PI) segment. The company announced a massive ₹1,000 Cr Phase 1 expansion at its 100-acre Vizag site to be invested over 3 years, representing approximately 115% of its TTM revenue. While gross margins contracted by 3% to 53% due to rising raw material costs, EBITDA margins improved to 33.5% on operating leverage. The company is nearing completion of its ₹250 Cr Mahad facility (Unit 3), which is expected to contribute commercially in H2 FY27.
Confidence: HIGH
What changedThe company has transitioned from a period of customer destocking in its PI segment to growth, while formalizing a massive multi-year capex plan at Vizag.
Why it mattersThe ₹1,000 Cr Vizag expansion is a transformative scale-up that exceeds the company's current annual revenue, aiming to shift Blue Jet toward a more complex, integrated CDMO platform.
Q1 FY27 Revenue: ₹293 CrVizag Phase 1 Capex: ₹1,000 CrCapex vs TTM Revenue: ~115%EBITDA Margin: 33.5%Mahad Project Total Cost: ₹250 Cr
📅 Short termThe sequential recovery in revenue and EBITDA margins, combined with the imminent launch of the Hyderabad R&D center, provides a positive outlook for the coming months.
📈 Long termThe structural shift toward vertical integration at Mahad and the large-scale Vizag expansion could significantly re-rate the business as it moves into complex APIs and high-potency manufacturing.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Raw material price volatility due to geopolitical factors
- Execution risk of the ₹1,000 Cr Vizag project
- Inventory build-up due to transit delays
Key Highlights
Q1 FY27 revenue grew 25% QoQ to ₹293 Cr, supported by normalized customer inventory in the PI segment.
Announced ₹1,000 Cr investment for Vizag Phase 1 over 3 years for contrast media and high-intensity sweeteners.
Unit 3 (Mahad) backward integration project is ahead of schedule with ₹210 Cr already invested out of ₹250 Cr total.
EBITDA margin expanded to 33.5% from 30.4% in the previous quarter despite raw material price headwinds.
Pipeline includes 3 new Contrast Media candidates for FY27 launch and 4 chronic therapy NCE programs in development.
👀 What to Watch
Investors should monitor the commissioning of the Mahad facility in H2 FY27 and the execution milestones of the ₹1,000 Cr Vizag project, which is the primary driver for long-term capacity growth.
₹78.3 Cr PAT: Blue Jet Healthcare Q1 FY27 Revenue Grows 25% QoQ; ₹800 Cr QIP Completed
Blue Jet Healthcare reported a sequential recovery in Q1 FY27 with revenue of ₹293.1 Cr, up 25% from Q4 FY26, though it remains 17% lower on a YoY basis. The sequential growth was primarily driven by the Pharma Intermediates & API segment, which saw revenue rise to ₹121 Cr from a low base of ₹2.4 Cr in the previous quarter. The company maintained strong EBITDA margins at 33.5% and successfully completed a ₹800 Cr QIP at ₹506 per share to fund its expansion plans. Key growth projects, including the Hyderabad R&D center and the 103-acre Vizag facility, are progressing as scheduled.
Confidence: HIGH
What changedThe company has transitioned from a weak Q4 FY26 to a stronger Q1 FY27 sequentially and has significantly bolstered its cash reserves through a ₹800 Cr fundraise.
Why it mattersThe sequential recovery in the PI & API segment and the successful fundraise provide the capital and momentum needed for the company's large-scale capacity expansions in Vizag and Mahad.
Q1 FY27 Revenue: ₹293.1 CrQ1 FY27 PAT: ₹78.3 CrQIP Fundraise: ₹800 CrQIP vs Market Cap: ~7.8%EBITDA Margin: 33.5%PI & API YoY Growth: -42.9%
📅 Short termThe market may react positively to the 25% sequential revenue growth and margin expansion, though the YoY decline in the PI segment remains a point of caution.
📈 Long termStructural growth is dependent on the execution of the Vizag project and the Mahad backward integration facility, both expected to contribute significantly from FY27 onwards.
⚠ Risk flags
- Significant YoY revenue decline in the Pharma Intermediates category
- High client concentration in the PI-API segment
- Historical issues with high inventory levels in Contrast Media
Key Highlights
Revenue from operations reached ₹293.1 Cr in Q1 FY27, a 25% sequential increase but a 17% YoY decline.
EBITDA margins improved to 33.5% in Q1 FY27 from 30.4% in the preceding quarter.
Completed a ₹800 Cr QIP at ₹506 per share, which represents approximately 7.8% of the current market capitalization.
Pharma Intermediates & API segment revenue grew to ₹121 Cr from ₹2.4 Cr in Q4 FY26, though down 43% YoY.
The Hyderabad R&D center is on track to be operational by September 2026.
👀 What to Watch
Monitor the commissioning of the Hyderabad R&D center in September 2026 and the utilization of the ₹800 Cr QIP proceeds for the Phase-I Vizag project.
Blue Jet Q1 FY27: Revenue Up 25% QoQ to ₹293 Cr; Completes ₹800 Cr QIP
Blue Jet Healthcare reported a sequential recovery in Q1 FY27 with revenue growing 25% QoQ to ₹293.1 Cr, although it remains 17.4% lower on a YoY basis. The growth was primarily driven by the Pharma Intermediates & API segment, which surged 57% YoY to ₹121 Cr, offsetting a 42.9% YoY decline in Contrast Media Intermediates. The company successfully raised ₹800 Cr via a QIP at ₹506 per share, significantly strengthening its cash position. EBITDA margins improved to 33.5% from 30.4% in the preceding quarter due to operating leverage.
Confidence: HIGH
What changedThe company has transitioned from a weaker Q4 FY26 to a stronger Q1 FY27 sequentially and has secured ₹800 Cr in fresh capital to fund its expansion plans.
Why it mattersThe successful QIP provides the necessary capital for the Vizag and Mahad expansions without increasing debt, while the growth in PI & API indicates successful diversification beyond contrast media.
Q1 FY27 Revenue: ₹293.1 CrQIP Fundraise: ₹800 CrQIP vs Market Cap: ~7.8%EBITDA Margin: 33.5%PI & API YoY Growth: 57%
📅 Short termThe stock may see neutral-to-positive sentiment as the market digests the sequential margin improvement and the successful completion of the large fundraise.
📈 Long termLong-term value creation depends on the successful scaling of the Vizag site and the Mahad backward integration facility, which are critical for margin sustainability and volume growth.
⚠ Risk flags
- Significant YoY decline (42.9%) in the Contrast Media segment
- High client concentration in the PI-API segment
- Regulatory risks in US and Europe impacting 76% of revenue
Key Highlights
Revenue from operations stood at ₹293.1 Cr, a 25% sequential increase from Q4 FY26.
Completed a ₹800 Cr fundraise through QIP by allotting 1,58,10,276 equity shares at ₹506 per share.
Pharma Intermediates & API segment revenue grew 57% YoY to ₹121 Cr.
Contrast Media Intermediates revenue declined 42.9% YoY to ₹115.9 Cr.
EBITDA margin improved to 33.5% in Q1 FY27 compared to 30.4% in Q4 FY26.
👀 What to Watch
Monitor the commissioning of the Hyderabad R&D center expected by September 2026 and the execution timeline of the 103-acre Vizag project. Investors should also track the volume recovery in the Contrast Media segment, which remains a core but currently volatile business driver.
₹1.2 Dividend & Q1 Results: Blue Jet Healthcare Reports ₹78.26 Cr PAT, Raises ₹800 Cr via QIP
Blue Jet Healthcare reported a 17.4% YoY decline in Q1 FY27 revenue to ₹293.11 cr, with PAT falling 14.2% to ₹78.26 cr. The company declared a dividend of ₹1.2 per share (60% of FV) with a record date of September 14, 2026. A significant development is the successful completion of an ₹800 cr QIP at ₹506 per share, which represents approximately 7.2% of its current market capitalization. The board also ensured leadership continuity by re-appointing the Executive Chairman and Managing Director for five-year terms starting April 2027.
Confidence: HIGH
What changedThe company has finalized its Q1 FY27 financial results, set the dividend record date, secured long-term leadership, and significantly strengthened its cash position through a large-scale fundraise.
Why it mattersThe ₹800 cr fundraise is material (7.2% of market cap) and provides the necessary capital for planned capacity expansions in the Contrast Media and PI-API segments, which are critical for reducing client concentration risks.
Q1 FY27 Revenue: ₹293.11 crQ1 FY27 PAT: ₹78.26 crDividend per share: ₹1.2QIP Fundraise: ₹800 crQIP vs Market Cap: ~7.2%Dividend Record Date: 14-Sep-2026
📅 Short termThe stock may face pressure due to the YoY decline in revenue and profit, though the dividend announcement and successful QIP completion at ₹506/share provide some support.
📈 Long termThe long-term outlook depends on the successful commissioning of the Mahad backward integration facility and the Vizag site to scale up production for innovator clients.
⚠ Risk flags
- YoY decline in quarterly revenue and profitability
- High client concentration risk
- Execution risk on large-scale capacity expansions
Key Highlights
Q1 FY27 revenue from operations decreased to ₹293.11 cr from ₹354.76 cr in the year-ago period.
Net profit for the quarter stood at ₹78.26 cr, down from ₹91.17 cr in Q1 FY26.
Successfully raised ₹800 cr through a Qualified Institutional Placement (QIP) of 1.58 cr shares at ₹506 each.
Declared a dividend of ₹1.2 per equity share (60% of face value ₹2) for the financial year 2025-26.
Re-appointed Akshay B Arora (Chairman) and Shiven Arora (MD) for 5-year terms effective April 2027.
👀 What to Watch
Investors should monitor the deployment of the ₹800 cr QIP proceeds toward the Vizag and Mahad expansion projects. The YoY decline in earnings warrants a close watch on the commissioning timelines of these new facilities to restore growth momentum.
Blue Jet Q1 Revenue at ₹293 Cr; Dividend Record Date Set for Sept 14, 2026
Blue Jet Healthcare reported a Q1 FY27 revenue of ₹293.11 cr, representing a 17.4% decline YoY but a 24.9% recovery from the previous quarter (Q4 FY26). Profit Before Tax (PBT) stood at ₹105.95 cr, down 13.8% YoY, though PBT margins remained healthy at 36.1%. The board confirmed a dividend of ₹1.2 per share (60% of face value) with a record date of September 14, 2026. Key leadership, including the Executive Chairman and Managing Director, have been re-appointed for five-year terms starting April 2027, ensuring management stability.
Confidence: HIGH
What changedThe company has reported its Q1 FY27 financial performance, set the dividend record date, and secured long-term management continuity through leadership re-appointments.
Why it mattersWhile YoY performance shows a decline, the QoQ recovery suggests stabilization; management continuity is vital for executing the large-scale Vizag and Mahad expansion projects.
Q1 FY27 Revenue: ₹293.11 crYoY Revenue Change: -17.4%QoQ Revenue Change: +24.9%Dividend per share: ₹1.2Record Date: September 14, 2026
📅 Short termThe stock may see neutral to slightly cautious sentiment due to the YoY revenue dip, though the dividend and QoQ growth provide a floor.
📈 Long termStructural growth depends on the successful scaling of the 103-acre Vizag site and the Mahad facility to reduce export concentration and improve supply chain efficiency.
⚠ Risk flags
- YoY contraction in both revenue and profitability
- High material costs relative to revenue in the current quarter
- Client concentration risks as noted in previous filings
Key Highlights
Q1 FY27 Revenue from operations stood at ₹293.11 cr, down from ₹354.76 cr in the same quarter last year.
Profit Before Tax for the quarter was ₹105.95 cr, compared to ₹122.86 cr in Q1 FY26.
Dividend of ₹1.2 per share (60% of face value) finalized with a record date of September 14, 2026.
Re-appointment of Mr. Akshay B Arora (Chairman) and Mr. Shiven Akshay Arora (MD) for 5-year terms until 2032.
Total expenses for the quarter were ₹202.40 cr, with material costs accounting for ₹178.88 cr.
👀 What to Watch
Investors should monitor the commissioning timeline of the Mahad backward integration facility in H2 FY26, which is critical for margin improvement and addressing the current YoY revenue contraction.
Blue Jet Q1 Revenue at ‡293 Cr; Re-appoints Top Management and Sets Dividend Record Date
Blue Jet Healthcare reported Q1 FY27 revenue of ‡293.11 cr, a 17.4% decline compared to ‡354.76 cr in the same quarter last year, though it showed a 24.9% recovery from the previous quarter. Profit Before Tax (PBT) stood at ‡105.95 cr, down 13.8% YoY, maintaining a healthy PBT margin of 36.1%. The board approved the re-appointment of the Executive Chairman and Managing Director for five-year terms starting April 2027. A dividend of ‡1.2 per share was finalized with a record date of September 14, 2026.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and secured leadership continuity by re-appointing its core promoter-management team for another five years.
Why it mattersWhile YoY performance is lower, the sequential (QoQ) recovery suggests stabilizing operations; management stability is crucial as the company enters a heavy capex commissioning phase in H2 FY26.
Q1 Revenue: ‡293.11 crYoY Revenue Change: -17.4%QoQ Revenue Change: +24.9%Dividend per share: ‡1.2Record Date: September 14, 2026
📅 Short termThe stock may see neutral to slightly cautious sentiment due to the YoY revenue dip, though the sequential improvement and dividend timeline provide a floor.
📈 Long termStructural growth depends on the successful scaling of the 103-acre Vizag site and reducing export concentration through new domestic products.
⚠ Risk flags
- Year-on-year revenue contraction
- High inventory levels (implied by ‡41.7 cr inventory increase in Q1)
- Client concentration risk
Key Highlights
Q1 FY27 Revenue from Operations reached ‡293.11 cr, down 17.4% from ‡354.76 cr in Q1 FY26.
Profit Before Tax for the quarter was ‡105.95 cr, showing a sequential growth of 21.6% over Q4 FY26.
Dividend of ‡1.2 per share (60% of face value) confirmed with a record date of September 14, 2026.
Executive Chairman Akshay B Arora and MD Shiven Akshay Arora re-appointed for 5-year terms until 2032.
Total Expenses for the quarter decreased to ‡202.40 cr from ‡240.15 cr in the year-ago period.
👀 What to Watch
Monitor the commissioning timeline of the Mahad backward integration facility and Vizag Phase-I in H2 FY26, as these are critical for reversing the YoY revenue decline.
Blue Jet Q1 Revenue at ₹293 Cr; Re-appoints Top Management and Sets Dividend Record Date
Blue Jet Healthcare reported a 17.4% YoY decline in Q1 FY27 revenue to ₹293.11 Cr, compared to ₹354.76 Cr in Q1 FY26. However, revenue showed a sequential recovery of 24.9% from the ₹234.67 Cr reported in Q4 FY26. Net profit for the quarter stood at ₹79.45 Cr, down 12.8% YoY. The board also approved the re-appointment of the Executive Chairman and Managing Director for five-year terms starting April 2027 and fixed September 14, 2026, as the record date for a ₹1.2 per share dividend.
Confidence: HIGH
What changedThe company released its Q1 FY27 financial results, confirmed long-term leadership continuity through 2032, and finalized the dividend payment schedule.
Why it mattersThe YoY decline in revenue and profit indicates potential volume or pricing pressure, but the sequential growth suggests a recovery from a weak Q4. Management continuity is crucial for executing the ongoing large-scale capacity expansions.
Q1 Revenue: ₹293.11 CrYoY Revenue Change: -17.4%QoQ Revenue Change: +24.9%Net Profit: ₹79.45 CrDividend per share: ₹1.2Record Date: September 14, 2026
📅 Short termThe stock may face pressure due to the YoY earnings decline, though the sequential improvement and dividend announcement provide some support.
📈 Long termStructural growth depends on the successful ramp-up of the 103-acre Vizag site and reducing export concentration through domestic market development.
⚠ Risk flags
- Year-on-year revenue and profit contraction
- High client concentration risk as noted in previous filings
- Inventory fluctuations impacting margins
Key Highlights
Revenue from operations for Q1 FY27 was ₹293.11 Cr, a 17.4% decrease from ₹354.76 Cr in Q1 FY26.
Net Profit for the quarter reached ₹79.45 Cr, resulting in a healthy net margin of 27.1%.
Executive Chairman Akshay B Arora and MD Shiven Akshay Arora re-appointed for 5-year terms (2027-2032).
Dividend of ₹1.2 per share (60% of face value) confirmed with a record date of September 14, 2026.
Total expenses for the quarter were ₹202.40 Cr, down from ₹240.15 Cr in the year-ago period.
👀 What to Watch
Investors should monitor the commissioning timeline of the Mahad backward integration facility and Vizag Phase-I in H2 FY26/FY27 to see if new capacity offsets the current YoY revenue contraction.
₹800 Cr QIP Allotment: Blue Jet Healthcare Issues 1.58 Cr Shares at ₹506/Share
Blue Jet Healthcare has successfully completed an ₹800 Cr fundraise through a Qualified Institutions Placement (QIP). The company allotted 15,810,276 equity shares at an issue price of ₹506 per share, which includes a 4.83% discount to the floor price. This capital infusion is highly material, representing approximately 92% of the company's TTM revenue and 59% of its net worth. Major institutional interest was seen from Shamyak Investment (34.38% of issue) and various ICICI Prudential Mutual Fund schemes (33.75% of issue).
Confidence: HIGH
What changedThe company has completed a significant equity fundraise, increasing its cash reserves by ₹800 Cr and expanding its equity base by approximately 9.1%.
Why it mattersThe fundraise provides the necessary capital to execute large-scale expansions like the Vizag site and Mahad backward integration without stressing the balance sheet, which currently has minimal debt (₹42 Cr).
Total Fundraise: ₹8,000 millionIssue Price: ₹506.00Fundraise vs TTM Revenue: ~92.4%Fundraise vs Net Worth: ~58.8%Equity Dilution: 9.11%
📅 Short termThe successful QIP with strong institutional participation (ICICI Pru) is likely to be viewed positively by the market, providing a liquidity cushion.
📈 Long termThe capital supports the company's strategy to scale up for innovator clients and reduce export concentration through new domestic products and massive capacity additions at Vizag.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution of ~9.1% will lead to immediate EPS contraction
- Execution risk associated with the large-scale Vizag Phase-I project
Key Highlights
Raised ₹800 Cr through the allotment of 15,810,276 equity shares to qualified institutional buyers.
Issue price fixed at ₹506 per share, representing a discount of ₹25.70 (4.83%) to the floor price.
Total paid-up equity shares increased by 9.11%, from 17.35 crore to 18.93 crore shares.
Shamyak Investment Private Limited emerged as the largest allottee, securing 34.38% of the total issue.
ICICI Prudential Mutual Fund schemes collectively acquired 33.75% of the shares offered in the QIP.
👀 What to Watch
Investors should monitor the deployment of these funds toward the 103-acre Vizag site and Mahad facility expansions. While the ~9% equity dilution will impact EPS in the near term, the focus should be on the timeline for commissioning new capacities.
₹800 Cr QIP Closure: Blue Jet Healthcare Allots 1.58 Cr Shares at ₹506/share
Blue Jet Healthcare has successfully closed its Qualified Institutions Placement (QIP), raising approximately ₹800 crore. The company allotted 15,810,276 equity shares at an issue price of ₹506.00 per share, which includes a 4.83% discount to the floor price of ₹531.70. This fundraise is highly material, representing approximately 58.8% of the company's net worth and 92.4% of its TTM revenue. The capital infusion is expected to support the company's aggressive expansion plans at its Vizag and Mahad facilities.
Confidence: HIGH
What changedThe company has completed a major capital raise through a QIP, resulting in an equity dilution of approximately 9% while significantly boosting its cash reserves.
Why it mattersThe fundraise provides the necessary capital to execute large-scale capacity expansions in the Contrast Media and PI-API segments, which are critical for the company's long-term growth strategy and innovator client relationships.
Total Fundraise: ₹800 CrIssue Price: ₹506.00Discount to Floor Price: 4.83%Fundraise vs TTM Revenue: ~92.4%Fundraise vs Net Worth: ~58.8%
📅 Short termThe stock may see some volatility as the market absorbs the ~9% equity dilution and the 4.83% discount to the floor price, but the successful institutional participation is a positive signal.
📈 Long termStructurally positive as the capital enables the company to scale its manufacturing footprint and reduce export concentration through new product development and backward integration.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution of existing shareholders
- Execution risk for the new Vizag and Mahad projects
Key Highlights
Allotted 15,810,276 equity shares of face value ₹2 each to qualified institutional buyers.
Issue price fixed at ₹506.00 per share, representing a total fundraise of ~₹800 crore.
Applied a discount of 4.83% (₹25.70 per share) to the SEBI-calculated floor price of ₹531.70.
Fundraise magnitude is significant at ~92% of TTM revenue (₹866 Cr) and ~59% of Net Worth (₹1,360 Cr).
👀 What to Watch
Investors should monitor the deployment of these funds toward the commissioning of the Mahad backward integration facility (H2 FY26) and the Phase-I development of the 103-acre Vizag site.
₹531.70 Floor Price: Blue Jet Healthcare Launches QIP to Raise Capital
Blue Jet Healthcare has officially launched its Qualified Institutions Placement (QIP) on July 6, 2026, setting a floor price of ₹531.70 per share. This floor price represents a ~3.6% discount to the current market price of ₹551.7. The company retains the option to offer an additional discount of up to 5% on the floor price to institutional buyers. This capital raise follows shareholder approval from June 17, 2026, and is likely intended to fund the company's significant ongoing expansions in Vizag and Mahad.
Confidence: HIGH
What changedThe company has transitioned from the approval phase to the execution phase of a major institutional fundraise.
Why it mattersThe fundraise will likely provide the capital needed for the company's aggressive expansion plans (Vizag and Mahad) while maintaining its low-debt profile (currently only ₹42 Cr debt vs ₹1,360 Cr net worth).
Floor Price: ₹531.70Current Market Price (CMP): ₹551.7Max Permissible Discount: 5%TTM Revenue: ₹866 CrNet Worth: ₹1,360 Cr
📅 Short termThe stock may experience price alignment toward the final QIP issue price in the coming days as institutional bidding concludes.
📈 Long termIf successfully deployed into the Vizag and Mahad facilities, this capital could significantly scale the company's PI-API and Contrast Media segments, supporting its high OPM of 33.7%.
⚠ Risk flags
- Equity dilution for existing shareholders
- Execution risk in commissioning new facilities on schedule
Key Highlights
Floor price fixed at ₹531.70 per equity share of face value ₹2 each
Company authorized to offer a discount of up to 5% on the calculated floor price
Issue officially opened on July 6, 2026, following Investment and Finance Committee approval
Relevant date for pricing determined as July 6, 2026, per SEBI ICDR Regulations
Fundraise follows a special resolution passed by shareholders on June 17, 2026
👀 What to Watch
Monitor the final issue price and the quality of institutional investors (allottees) to gauge market confidence. Track the deployment of these funds toward the H2 FY26 commissioning of the Mahad facility and the 103-acre Vizag site.
Blue Jet Healthcare Shareholders Approve Fundraise via Equity Issuance with 99.99% Majority
Blue Jet Healthcare Limited has received overwhelming shareholder approval to raise funds through the issuance of equity shares or other eligible securities in one or more tranches. During the Extraordinary General Meeting held on June 17, 2026, the special resolution passed with 99.9999% of the 143.89 million votes cast in favor. Both the promoter group and public institutional investors showed 100% support for the proposal, providing the company with a clear mandate for capital expansion.
Key Highlights
Shareholders approved a special resolution for raising funds through the issuance of Equity Shares and/or other Eligible Securities.
The resolution received 143,893,328 votes in favor (99.9999%) and only 134 votes against.
Promoter and Promoter Group cast 138,445,696 votes, representing 100% support from this category.
Public Institutional investors also provided 100% support with 5,444,170 votes in favor.
The total number of shareholders on the record date (June 10, 2026) was 78,569.
👀 What to Watch
Investors should watch for upcoming announcements regarding the specific amount of capital to be raised and the pricing of the securities, as these factors will determine the extent of equity dilution and the company's growth trajectory.
Blue Jet Healthcare Shareholders Approve Fundraise via Equity Issuance at EGM
Blue Jet Healthcare Limited conducted an Extraordinary General Meeting (EGM) on June 17, 2026, to seek shareholder approval for raising capital. The primary agenda was a special resolution to issue equity shares or other eligible securities in one or more tranches. The meeting was held via video conferencing, and management addressed various shareholder queries regarding the company's plans. Final voting results are expected to be released within the stipulated legal timeframe following the scrutinizer's report.
Key Highlights
Proposed a special resolution for raising funds through the issuance of Equity Shares and/or other Eligible Securities.
The EGM was held on June 17, 2026, with remote e-voting conducted from June 14 to June 16, 2026.
Top management including the Executive Chairman, Managing Director, and CFO were present to interact with shareholders.
The fundraise is intended to be executed in one or more tranches, indicating potential for significant capital infusion.
👀 What to Watch
Investors should monitor the upcoming disclosure of the voting results and subsequent board decisions regarding the size and pricing of the fundraise. The capital infusion could signal expansion plans, though it may lead to equity dilution.
Blue Jet Healthcare FY26 Revenue Dips 8% to ₹947 Cr; Plans ₹1,000 Cr Vizag Capex
Blue Jet Healthcare reported FY26 revenue of ₹947 crores, an 8% YoY decline, largely due to a 35% slump in the Pharma Intermediates segment caused by customer destocking. The Contrast Media segment provided a cushion with 23% YoY growth, reaching ₹495 crores. EBITDA margins contracted to 31% from 37% in the previous year, though the company remains debt-free with ₹400 crores in cash. Management is pivoting towards growth with a ₹1,000 crore greenfield expansion in Vizag and a new R&D center in Hyderabad.
Key Highlights
FY26 Revenue declined 8% YoY to ₹947 crores, while Q4 revenue rose 22% QoQ to ₹235 crores.
Contrast Media segment revenue grew 23% to ₹495 crores, offsetting a 35% decline in PI/API segment.
EBITDA margin compressed to 31% in FY26 compared to 37% in FY25 due to lower volumes.
Announced ₹1,000 crore capex for Vizag greenfield project over 3 years and ₹400 crore spend for FY27.
Company remains debt-free with liquid financial assets of ₹400 crores as of March 2026.
👀 What to Watch
Monitor the recovery of the Pharma Intermediates segment and the execution of the Vizag capex, which are critical for future growth. The current margin compression suggests a period of consolidation before new capacities go live in FY27.
Blue Jet Healthcare Proposes ₹1,000 Crore Fundraise via QIP and Other Securities
Blue Jet Healthcare Limited has scheduled an Extraordinary General Meeting (EGM) on June 17, 2026, to seek shareholder approval for raising funds up to ₹10,000 million (₹1,000 crore). The capital is intended to be raised in one or more tranches through the issuance of equity shares, convertible debentures, or other eligible securities. The methods mentioned include Qualified Institutions Placement (QIP), preferential issues, or private placements. This move suggests the company is preparing for significant capital expenditure or expansion initiatives.
Key Highlights
Proposed fundraise of up to ₹10,000 million (₹1,000 crore) through various equity-linked instruments.
Extraordinary General Meeting (EGM) scheduled for June 17, 2026, to obtain necessary shareholder approvals.
Fundraising routes include Qualified Institutions Placement (QIP), preferential issues, and private placements.
The Board may offer a discount of up to 5% on the floor price for QIP allotments as per SEBI regulations.
Allotment of securities under the QIP must be completed within 365 days from the date of the special resolution.
👀 What to Watch
Investors should monitor the specific end-use of the ₹1,000 crore and the eventual pricing of the issue to assess the extent of equity dilution. The large scale of the fundraise indicates aggressive growth plans which could be a long-term value driver.
Blue Jet Healthcare Q4 PAT Surges 60% QoQ to ₹643 Mn; FY26 Revenue Dips 8% YoY
Blue Jet Healthcare reported a strong sequential recovery in Q4 FY26, with PAT rising 60% QoQ to ₹643 million, driven by higher sales of Advanced Contrast Media. However, on a full-year basis, FY26 revenue declined by 8% to ₹9,473 million, primarily due to a 35.6% slump in the Pharma Intermediates & API segment caused by customer-side inventory normalization. The Contrast Media segment remained a bright spot, growing 22.6% YoY for the full year. Management indicates that the de-stocking phase in the PI segment is now complete, with robust orders expected in upcoming quarters.
Key Highlights
Q4 FY26 EBITDA margins improved to 30.4% from 24.4% in Q3 FY26 due to operating leverage and product mix.
Contrast Media Intermediates segment grew 22.6% YoY in FY26, contributing ₹4,951 million to the top line.
Pharma Intermediates & API revenue fell 35.6% YoY in FY26 to ₹2,978 million due to timing-related order phasing.
Maintains a strong balance sheet with Cash and Treasury Investments of ₹3,619 million as of March 31, 2026.
Expansion projects in Vizag and the Hyderabad R&D center are underway, with the R&D center expected by September 2026.
👀 What to Watch
Investors should focus on the recovery of the Pharma Intermediates segment in FY27, as management claims inventory normalization is over. The steady growth in the core Contrast Media business and strong cash position provide a healthy margin of safety.
Blue Jet Healthcare Starts 1,000 Cr Vizag Facility; Total Potential Investment 2,300 Cr
Blue Jet Healthcare has officially commenced the construction of its new manufacturing facility in Vizag, Andhra Pradesh, with an initial Phase 1 investment of 1,000 crore. The project has a long-term development potential of up to 2,300 crore, subject to future milestones and regulatory approvals. This facility will focus on high-margin complex pharmaceutical intermediates and APIs for global innovators. The expansion is a key part of the company's multi-decade growth strategy to strengthen its global supply chain position.
Key Highlights
Phase 1 investment of 1,000 crore approved by the Board of Directors
Total long-term investment potential estimated at 2,300 crore across multiple phases
Focus on manufacturing complex pharmaceutical intermediates and active pharmaceutical ingredients (APIs)
Facility located at Industrial Park Rambilli Cluster Phase II in Anakapalli District, Andhra Pradesh
Strategic move to enhance capabilities as a global supplier to pharmaceutical innovators
👀 What to Watch
Investors should view this as a significant long-term growth catalyst that will substantially increase production capacity. Monitor the project's execution timeline and future commissioning dates for revenue visibility.
Blue Jet Healthcare to Hold Groundbreaking Ceremony for New Andhra Pradesh Facility
Blue Jet Healthcare Limited has scheduled the groundbreaking ceremony (Bhoomi Pujan) for its new manufacturing plot in Andhra Pradesh for February 28, 2026. Located at Industrial Park Rambilli Cluster Phase II, this project is a key part of the company's long-term growth strategy first announced in July 2025. The new facility is intended to significantly strengthen the company's infrastructure to meet rising global market demands. This move signals management's confidence in future order pipelines and capacity requirements.
Key Highlights
Groundbreaking ceremony for the new manufacturing facility scheduled for February 28, 2026.
Project located at Industrial Park Rambilli Cluster Phase II, Anakapalli District, Andhra Pradesh.
Follow-up to the initial strategic expansion intimation provided on July 31, 2025.
Facility aimed at enhancing infrastructure to address growing market demands in the healthcare sector.
👀 What to Watch
Investors should view this as a positive step toward long-term capacity building and monitor future updates regarding the project's capital expenditure and expected commissioning date.
Blue Jet Healthcare Q3 FY26 PAT Drops 59% YoY to ₹402 mn Amid Margin Pressure
Blue Jet Healthcare reported a weak Q3 FY26 with revenue falling 40% YoY to ₹1,924 mn and PAT declining 59% YoY to ₹402 mn. The performance was severely impacted by inventory de-stocking in the Pharma Intermediates segment and a shift in product mix, causing EBITDA margins to contract to 24.4% from 39% a year ago. Despite the quarterly slump, 9M FY26 revenue grew slightly by 3% YoY to ₹7,127 mn. Strategically, the company secured land in Vizag and a new R&D center in Hyderabad to support long-term expansion.
Key Highlights
Q3 FY26 Revenue fell 40% YoY to ₹1,924 mn due to lower sales in Pharma Intermediates and Sweeteners.
EBITDA margins compressed significantly to 24.4% in Q3 FY26 compared to 39.0% in Q3 FY25.
Pharma Intermediates segment revenue plummeted to ₹257 mn from ₹1,465 mn YoY due to customer de-stocking.
9M FY26 PAT stood at ₹1,835 mn, a 6% YoY decrease, while 9M revenue grew 3% to ₹7,127 mn.
Company executed a 10-year lease for a 57,240 sq.ft. R&D center in Hyderabad and took possession of Vizag land.
👀 What to Watch
Investors should exercise caution as the sharp decline in margins and Pharma Intermediate sales indicates significant near-term headwinds. Monitor the pace of inventory re-stocking at the customer end and the execution of the new R&D and Vizag facilities for signs of recovery.
Blue Jet Healthcare Assigned CARE A+; Stable / CARE A1+ Rating for ₹275 Cr Bank Facilities
CARE Ratings has assigned a 'CARE A+; Stable' long-term and 'CARE A1+' short-term rating to Blue Jet Healthcare's ₹275 crore bank facilities, reflecting its strong financial profile. The company demonstrated robust growth in FY25, with Total Operating Income rising to ₹1,048.29 crore and PBILDT margins improving to 37.78%. While the company remains virtually debt-free with a gearing of 0.02x, it faces high customer concentration with the top 5 clients contributing 79% of revenue. A significant ₹1,300 crore capex plan is underway over the next 3-4 years to drive future expansion.
Key Highlights
Assigned CARE A+ (Stable) and CARE A1+ ratings for ₹275 crore bank facilities.
FY25 Total Operating Income grew to ₹1,048.29 crore from ₹721.53 crore in FY24.
PBILDT margins improved to 37.78% in FY25, supported by high-value CDMO services.
Strong liquidity with ₹269.81 crore in cash and liquid investments and negligible external debt.
High product concentration risk with Bempedoic Acid intermediate accounting for ~45% of total income.
👀 What to Watch
The investment-grade rating validates the company's strong balance sheet and niche market leadership in contrast media intermediates. Investors should monitor the progress of the ₹1,300 crore capex and the company's ability to diversify its revenue base beyond its top five customers.
